Core Viewpoint - GENFIT has received Orphan Drug Designation (ODD) from the U.S. FDA for its investigational drug NTZ (nitazoxanide) aimed at treating Acute-on-Chronic Liver Failure (ACLF), a severe condition with no approved therapies [1][6]. Group 1: Drug Development and Clinical Trials - G1090N is GENFIT's lead investigational program targeting ACLF, recognized by the FDA for its potential to address this life-threatening condition characterized by rapid deterioration and high mortality [2][6]. - Recent Phase 1 data showed a favorable safety and tolerability profile for G1090N in healthy volunteers, along with significant anti-inflammatory activity in ex vivo models, supporting the advancement to Phase 2 clinical development expected in the second half of 2026 [3][6]. Group 2: Regulatory and Market Implications - The ODD designation provides GENFIT with various development incentives, including FDA regulatory guidance, user fee reductions, and eligibility for seven-year U.S. market exclusivity upon FDA approval [3][6]. - The company aims to leverage this designation to enhance its development strategy and prospects in the ACLF segment, which is critical given the unmet medical needs in this area [5][6]. Group 3: Company Background and Focus - GENFIT is a biopharmaceutical company focused on rare and life-threatening liver diseases, with over two decades of research and development experience [4]. - The company also targets other serious conditions such as cholangiocarcinoma, urea cycle disorders, and organic acidemias, maintaining a diverse R&D portfolio [4].

Core Insights - The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GENFIT's investigational drug NTZ (nitazoxanide) for the treatment of Acute-on-Chronic Liver Failure (ACLF), a severe condition with no approved therapies [1][6] Company Overview - GENFIT is a biopharmaceutical company focused on rare and life-threatening liver diseases, with over two decades of research and development experience [4] - The company is headquartered in Lille, France, and has additional offices in Paris, Zurich, and Cambridge, MA [4] - GENFIT's R&D portfolio includes therapeutic assets targeting ACLF, acute decompensation (AD), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorders (UCD), and organic acidemias (OA) [4] Drug Development and Clinical Trials - G1090N is GENFIT's lead investigational program within the ACLF segment, recognized by the FDA for its potential to address this severe condition characterized by rapid deterioration and high short-term mortality [2][3] - Recent Phase 1 data showed a favorable safety and tolerability profile in healthy volunteers, along with strong anti-inflammatory activity in ex vivo models, supporting the advancement to Phase 2 clinical development targeted for the second half of 2026 [3][6] Regulatory Incentives - The ODD designation provides GENFIT with several development incentives, including FDA regulatory guidance, user fee reductions, and eligibility for seven-year U.S. market exclusivity upon FDA approval [3]